BACKGROUND: Treatment options for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are limited with response rates to cytotoxic chemotherapy of approximately 30% and median survival of 6 months. PATIENTS AND METHODS: In a multicentre phase II study, 32 patients with recurrent or metastatic HNSCC received 3-AP Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), an inhibitor of ribonucleotide reductase, 96 mg/m2, daily for 4 days every 14 days (one cycle). Eligibility criteria required Eastern Cooperative Oncology Group performance status (ECOG PS) of zero to two with a life expectancy of >3 months; one prior chemotherapy regimen was allowed. RESULTS: Thirty patients were assessable for response and toxicity. Median age was 57 years (range 36-79) and median ECOG PS was one (range 0-2). Thirteen patients had previously been treated with chemotherapy. A total of 130 cycles were administered with a median number of cycles of 3.5 (range 1-8). Mild anaemia (40%), nausea (22%) and fatigue (22%) were commonly reported with G3 and G4 neutropenia documented in 22% and 22%, respectively. Overall response rate was 5.9% (95% confidence interval 0.2% to 28.7%). One patient achieved a partial response, eight had stable disease and 21 progressive disease. Median time to disease progression was 3.9 months. CONCLUSIONS: 3-AP Triapine as a single agent, at this dose and schedule, is well tolerated but has only minor activity in the treatment of advanced HNSCC.
BACKGROUND: Treatment options for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are limited with response rates to cytotoxic chemotherapy of approximately 30% and median survival of 6 months. PATIENTS AND METHODS: In a multicentre phase II study, 32 patients with recurrent or metastatic HNSCC received 3-AP Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone), an inhibitor of ribonucleotide reductase, 96 mg/m2, daily for 4 days every 14 days (one cycle). Eligibility criteria required Eastern Cooperative Oncology Group performance status (ECOG PS) of zero to two with a life expectancy of >3 months; one prior chemotherapy regimen was allowed. RESULTS: Thirty patients were assessable for response and toxicity. Median age was 57 years (range 36-79) and median ECOG PS was one (range 0-2). Thirteen patients had previously been treated with chemotherapy. A total of 130 cycles were administered with a median number of cycles of 3.5 (range 1-8). Mild anaemia (40%), nausea (22%) and fatigue (22%) were commonly reported with G3 and G4 neutropenia documented in 22% and 22%, respectively. Overall response rate was 5.9% (95% confidence interval 0.2% to 28.7%). One patient achieved a partial response, eight had stable disease and 21 progressive disease. Median time to disease progression was 3.9 months. CONCLUSIONS:3-AP Triapine as a single agent, at this dose and schedule, is well tolerated but has only minor activity in the treatment of advanced HNSCC.
Authors: Ahmed Diab; Michael Kao; Keffy Kehrli; Hee Yeon Kim; Julia Sidorova; Eduardo Mendez Journal: Mol Cancer Res Date: 2019-01-24 Impact factor: 5.852
Authors: Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti Journal: Annu Rev Nutr Date: 2018-08-21 Impact factor: 11.848
Authors: Christian R Kowol; Petra Heffeter; Walter Miklos; Lars Gille; Robert Trondl; Loredana Cappellacci; Walter Berger; Bernhard K Keppler Journal: J Biol Inorg Chem Date: 2011-12-22 Impact factor: 3.358
Authors: Jill M Kolesar; Kamakshi Sachidanandam; William R Schelman; Jens Eickhoff; Kyle D Holen; Anne M Traynor; Dona B Alberti; James P Thomas; Christopher R Chitambar; George Wilding; William E Antholine Journal: Exp Ther Med Date: 2011-01 Impact factor: 2.447
Authors: Anand Joshi; Brian F Kiesel; Nupur Chaphekar; Reyna Jones; Jianxia Guo; Charles A Kunos; Sarah Taylor; Edward Chu; Raman Venkataramanan; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2020-09-28 Impact factor: 3.333
Authors: Mikael Crona; Paula Codó; Venkateswara Rao Jonna; Anders Hofer; Aristi P Fernandes; Fredrik Tholander Journal: Mol Oncol Date: 2016-07-26 Impact factor: 6.603